MTSI involved immunizing BALB/c mice with CFA from Pb18 as a tolerogen and Pl01 as an immunogen, using Freund's adjuvant and cyclophosphamide to induce immune tolerance...The effective generation of P. lutzii-specific antibodies by MTSI demonstrates this technology's promise for the development of accurate PCM diagnostic instruments. These antibodies have the potential to enhance patient outcomes and reduce the incidence of false-negative diagnoses, which could lead to better disease management.

Targeting LDHA and disrupting lactate metabolism and its signaling pathways can effectively enhance the sensitivity of LUAD to Lobaplatin, providing a promising approach to overcoming multidrug resistance. These findings offer valuable insights into developing new treatment strategies for lung adenocarcinoma, emphasizing the role of metabolic pathways in cancer therapy.

P1, N=25, Not yet recruiting, St. Jude Children's Research Hospital | Trial completion date: Dec 2031 --> Dec 2032 | Trial primary completion date: Dec 2028 --> Dec 2029

P2, N=20, Recruiting, Northside Hospital, Inc. | Not yet recruiting --> Recruiting

P=N/A, N=50, Recruiting, The University of Hong Kong | Unknown status --> Recruiting | Trial completion date: Jun 2021 --> Dec 2028 | Trial primary completion date: Mar 2021 --> Dec 2028

Procarbazine induces a higher mutation burden and novel mutational signatures in patients with Hodgkin lymphoma treated with eBEACOPP and their germline DNA, raising concerns for the genomic health of survivors of Hodgkin lymphoma and hereditary consequences for their offspring. However, replacing procarbazine with dacarbazine appears to mitigate gonadal and stem-cell toxicity while maintaining similar clinical efficacy.

P2, N=27, Recruiting, University of Illinois at Chicago | Trial completion date: Nov 2024 --> Dec 2026 | Trial primary completion date: Nov 2024 --> Dec 2026

P2, N=55, Active, not recruiting, Chinese University of Hong Kong | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2025

P3, N=180, Recruiting, Luye Pharma Group Ltd. | Not yet recruiting --> Recruiting

Concomitant NAMPT inhibition further compounded the effects of NAPRT KO, effectively sensitizing MM cells to the chemotherapeutic drug, melphalan; NAPRT added-back fully rescues these phenotypes. Overall, our results propose comprehensive NAD+ biosynthesis inhibition, through simultaneously targeting NAMPT and NAPRT, as a promising strategy to be tested in randomized clinical trials involving transplant-eligible MM patients, especially those with more aggressive disease.

P=N/A, N=26, Completed, University of Turin, Italy | Recruiting --> Completed | N=100 --> 26 | Trial completion date: Sep 2022 --> Dec 2024

P1, N=13, Recruiting, Peking University Cancer Hospital & Institute

Interestingly, our study shows that lurbinectedin treatment upregulates MHC-I/II genes and CD8 in SCLC clinical samples. We provide mechanistic insights into the effect of lurbinectedin on STING-mediated multimodal immune activation and demonstrate that lurbinectedin treatment represents a promising therapeutic strategy to potentiate the efficacy of immunotherapy in SCLC.

Upon cleavage by tumor-cell-overexpressed carboxylesterase, chlorambucil (Cbl) can be released to induce tumor cell apoptosis and activate caspase-3. This activation triggers the production of the near-infrared dye Hcy-NH2, generating both near-infrared fluorescence and photoacoustic signals for monitoring the apoptosis process. The excellent "theranostic correlation" between the imaging signal and therapeutic response, as demonstrated in orthotopic breast tumors, highlights the potential of Cbl-DEVD-Hcy for effective tumor therapy and precise CDx in the body.

P=N/A, N=15, Active, not recruiting, University of Sao Paulo General Hospital | Recruiting --> Active, not recruiting

P2, N=23, Completed, Italian Sarcoma Group | Active, not recruiting --> Completed

The first-line treatment for LGL leukemia is historically based on immunosuppressive agents (methotrexate, cyclophosphamide, or cyclosporine). However, cytokines blocking molecules or Jak/STAT inhibitors represent a new conceptual therapeutic approach for LGL leukemia. In this review, we present an overview of the spectrum of LGL proliferations, potential links between LGL expansion and autoimmunity, and therapeutic approaches.

P1/2, N=48, Active, not recruiting, Sarcoma Alliance for Research through Collaboration | Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Jun 2024 --> Jun 2025

P2, N=27, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Dec 2026 --> Dec 2028 | Trial primary completion date: Dec 2024 --> Dec 2027

P2, N=81, Terminated, Beijing Boren Hospital | Active, not recruiting --> Terminated; ethic commitee decision

P1, N=5, Active, not recruiting, Mayo Clinic | N=18 --> 5 | Trial completion date: Oct 2025 --> Aug 2028 | Trial primary completion date: Oct 2024 --> Aug 2027 | Recruiting --> Active, not recruiting

P2, N=29, Not yet recruiting, University of Alabama at Birmingham | Initiation date: Nov 2024 --> Jun 2025 | Trial primary completion date: Jan 2026 --> Dec 2026

P2, N=130, Completed, Italian Sarcoma Group | Active, not recruiting --> Completed

P1, N=28, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Nov 2024 --> Nov 2025 | Trial primary completion date: Nov 2024 --> Nov 2025

P=N/A, N=20, Recruiting, Samsung Medical Center | Trial primary completion date: Jul 2023 --> Jul 2025

P1, N=6, Active, not recruiting, Vastra Gotaland Region | Recruiting --> Active, not recruiting

P2, N=108, Active, not recruiting, City of Hope Medical Center | Recruiting --> Active, not recruiting

P2, N=198, Not yet recruiting, UNICANCER | Initiation date: Oct 2024 --> Feb 2025

Moreover, the effects observed in POF mice were enhanced, including an increasing in the number of growing ovarian follicles, regulation of serum hormone levels, and alterations in signaling pathways, as evidenced by the up-regulation of Phosphatidylinositol 3-kinase/Protein Kinase B (PI3K/Akt) and B cell lymphoma-2/ Bcl-associated x protein (Bcl-2/Bax) pathways, alongside the down-regulation of the mitogen-activated protein kinases (MAPK) signaling pathway. Sturgeon swim bladder collagen (peptide) could protect against cyclophosphamide-induced POF in mice, which could be very beneficial in the future advancement of health products.

Furthermore, we reveal a reduction in PARP1/PARP2 levels in ARH3-deficient cells treated with PARG inhibitor due to excessive ADP-ribosylation, which may contribute to alkylating agents' vulnerability. Collectively, these results uncover the potential of targeting ADP-ribosyl hydrolases in combination with alkylating agents for cancer therapy and provide insights into the mechanisms underlying the synthetic lethal effect.

We used cyclophosphamide (CTX) to construct the immunosuppressive mice model and then inoculated them with CT26 cells to build the CT26 tumor-bearing immunosuppression mice model...These results indicated that SEP activated the immune activity of RAW 264.7 macrophages through the TLR4-mitogen-activated protein kinase (MAPK)/nuclear factor kappa B (NF-κB) signaling pathway to exert immunomodulatory function and inhibit tumor proliferation. This study facilitated the further application of SEP as a potential immunomodulatory and anti-tumor functional food.

LEV can be helpful as an adjuvant in cancer patients who are on CP treatment, to minimize toxicity. However, its role in in-vivo cancer model is further needed to be confirmed.

Phytosphingosine and sphinganine are honey constituents which may be linked to the increased cytotoxicity of CP observed in A549 cells. This study provides further knowledge on the molecular basis by which A. dorsata honey potentiates the cytotoxic effect of cyclophosphamide in A549 cells.

This restoration brought the gut microbiota back to normal levels and increased the abundance of certain tumor-inhibiting bacteria, such as Alistipes. Overall, lentinan demonstrated the ability to reverse the immunosuppressive effects induced by cyclophosphamide and modulate gut microbiota to restore a healthy microbial balance.

Based on these findings, orally administered LRa05 could effectively maintain intestinal microbiota homeostasis and regulate immunity, suggesting the potential of L. rhamnosus LRa05 as a candidate probiotic strain in the application of dietary supplement. PRACTICAL APPLICATION: Supplement with L. rhamnosus LRa05 can improve immunity, regulate gut microbiota and promote body health.

These findings explain the unusual mechanism underlying trabectedin's effectiveness against MLPS by pinpointing the chimera's role in inducing the differentiation block responsible for MLPS pathogenesis. Additionally, the findings hint at a potential mechanism of resistance acquired in vivo.

P3, N=316, Active, not recruiting, Shanghai Jiao Tong University School of Medicine

This is a retrospective study including patients with stage III breast cancer who received neoadjuvant chemotherapy consisting of doxorubicin 60 mg/m² plus cyclophosphamide 600 mg/m², followed by paclitaxel 175 mg/m² every two weeks at Vietnam National Cancer Hospital and Hanoi Oncology Hospital between January 2015 and December 2022. Low cT stage, grade 3, and hormone receptor-negative status were independent predictors of pCR. Hormone receptor-positive status and pCR were independent prognostic factors for better EFS, while hormone receptor-positive status was the only independent prognostic factor for better OS.

ZGP protects ovarian function in CTX-induced ovarian aging rats by regulating the Notch1/Nrf2 pathway. It restores serum sex hormone levels, maintains normal follicle development, promotes the proliferation of aged OSCs, optimizes the cell cycle, reduces apoptosis, and preserves stemness, thereby alleviating ovarian aging.

Case 1: A 44-year-old male started trabectedin as second-line therapy after initial chemotherapy, which included doxorubicin. He then began trabectedin and has maintained a response for 10 months to date. Compared to other chemotherapies, trabectedin demonstrated potentially higher efficacy and a favorable safety profile for patients with myxoid liposarcoma harboring the FUS/CHOP fusion gene.

P1, N=18, Recruiting, The First Affiliated Hospital of Soochow University

P2, N=72, Completed, Ain Shams University | Recruiting --> Completed